Resources
99 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2024
The Alcohol-Related Disease Impact (ARDI) is an online application from the Centers for Disease Control and Prevention (CDC) that provides national and state estimates of alcohol-related health impacts, including deaths and years of potential life lost (YPLL).
Posted 5/5/2024 (updated 5/7/2024)
The U.S. Department of Health & Human Services released details of a plan for more than 200 actions across the federal government to address high rates of suicide.
Posted 5/5/2024 (updated 5/7/2024)
The MaineHealth Substance Use Training team has created a toolkit for extended-release injectable buprenorphine (Sublocade).
Posted 4/4/2024 (updated 4/18/2024)
If you or someone else is in immediate danger, call 911 to seek immediate assistance.
Below are resources you can contact if you are seeking assistance or information. All resources are intended for informational purposes only.
Posted 6/2/2021 (updated 4/10/2024)
This webinar provided a review of basic principles of integrated behavioral health and an update on recent outcomes and implementation research.
Posted 5/17/2021 (updated 4/10/2024)
This webinar will present the OUD Cascade of Care, explain how to create one for your program and use it to evaluate and sustain your MOUD continuum of care.
Learning Objectives:
Understand the cascade of care for opioid use disorder (OUD)
Define metrics for your OUD cascade of care
Use the cascade of care to take action that improves sustainability
Target Audience: Implementation I, Implementation II, MAT Expansion, but all cohorts are welcome
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 4/19/2021 (updated 4/5/2024)
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.